{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:11:07Z","timestamp":1788473467748,"version":"build-2803163510"},"reference-count":26,"publisher":"Siapec Servizi Srl","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-n979","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:06:36Z","timestamp":1763391996000},"page":"338-347","source":"Crossref","is-referenced-by-count":5,"title":["SPOP and MMR\/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression"],"prefix":"10.32074","volume":"117","author":[{"given":"Vincenzo","family":"Fiorentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"German\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Capodimonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Zuccal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ficarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pizzimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Dolci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"10.32074\/1591-951X-N979_ref1","doi-asserted-by":"crossref","unstructured":"Meng J, Zhou Y, Lu X, et al. Immune response drives outcomes in prostate cancer: implications for immunotherapy. Mol Oncol. 2021;15:1358-1375. https:\/\/doi.org\/10.1002\/1878-0261.12887.","DOI":"10.1002\/1878-0261.12887"},{"key":"10.32074\/1591-951X-N979_ref2","doi-asserted-by":"crossref","unstructured":"Maselli FM, Giuliani F, Laface C, et al. Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives. Curr Oncol. 2023;30(:5769-5794. https:\/\/doi.org\/10.3390\/curroncol30060432.","DOI":"10.3390\/curroncol30060432"},{"key":"10.32074\/1591-951X-N979_ref3","doi-asserted-by":"crossref","unstructured":"Geng C, Rajapakshe K, Shah SS, et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014;74:5631-43. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0476.","DOI":"10.1158\/0008-5472.CAN-14-0476"},{"key":"10.32074\/1591-951X-N979_ref4","doi-asserted-by":"crossref","unstructured":"An J, Wang C, Deng Y, et al. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014;6:657-69. https:\/\/doi.org\/10.1016\/j.celrep.2014.01.013.","DOI":"10.1016\/j.celrep.2014.01.013"},{"key":"10.32074\/1591-951X-N979_ref5","doi-asserted-by":"crossref","unstructured":"Yang X, Zhu Q. SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic Implications. Genes 2022;13:2051. https:\/\/doi.org\/10.3390\/genes13112051.","DOI":"10.3390\/genes13112051"},{"key":"10.32074\/1591-951X-N979_ref6","doi-asserted-by":"crossref","unstructured":"Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature;553:91-95. https:\/\/doi.org\/10.1038\/nature25015.","DOI":"10.1038\/nature25015"},{"key":"10.32074\/1591-951X-N979_ref7","doi-asserted-by":"crossref","unstructured":"Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas Haet al., Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019 Apr 1;5(4):471-478. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5801. PMID: 30589920; PMCID: PMC6459218.","DOI":"10.1001\/jamaoncol.2018.5801"},{"key":"10.32074\/1591-951X-N979_ref8","doi-asserted-by":"crossref","unstructured":"Zhang H, Yang X, Xie J, Cheng X, Chen J, Shen M, et al. Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China. Front Oncol. 2023 Oct 13;13:1277233. https:\/\/doi.org\/10.3389\/fonc.2023.1277233. PMID: 37901334; PMCID: PMC10613026.","DOI":"10.3389\/fonc.2023.1277233"},{"key":"10.32074\/1591-951X-N979_ref9","doi-asserted-by":"crossref","unstructured":"Palicelli A, Croci S, Bisagni A, et al. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. Biomedicines. 2022;10:236. https:\/\/doi.org\/10.3390\/biomedicines10020236.","DOI":"10.3390\/biomedicines10020236"},{"key":"10.32074\/1591-951X-N979_ref10","doi-asserted-by":"crossref","unstructured":"McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-4. https:\/\/doi.org\/10.1093\/jnci\/dji237.","DOI":"10.1093\/jnci\/dji237"},{"key":"10.32074\/1591-951X-N979_ref11","doi-asserted-by":"crossref","unstructured":"Martini M, Cenci T, D\u2019Alessandris GQ, et al. Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer. 2013;119:1004-12. https:\/\/doi.org\/10.1002\/cncr.27821.","DOI":"10.1002\/cncr.27821"},{"key":"10.32074\/1591-951X-N979_ref12","doi-asserted-by":"crossref","unstructured":"Zurlo IV, Schino M, Strippoli A, et al. Predictive value of NLR, TILs (CD4+\/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Cancer Immunol Immunother. 2022;71:45-55. https:\/\/doi.org\/10.1007\/s00262-021-02960-1.","DOI":"10.1007\/s00262-021-02960-1"},{"key":"10.32074\/1591-951X-N979_ref13","doi-asserted-by":"crossref","unstructured":"Cerbelli B, Girolami I, Eccher A, et al. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. Histopathology. 2022;80:397-406. https:\/\/doi.org\/10.1111\/his.14562.","DOI":"10.1111\/his.14562"},{"key":"10.32074\/1591-951X-N979_ref14","doi-asserted-by":"crossref","unstructured":"Buccarelli M, Lulli V, Giuliani A, et al. Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro Oncol. 2020;22:1771-1784. https:\/\/doi.org\/10.1093\/neuonc\/noaa127.","DOI":"10.1093\/neuonc\/noaa127"},{"key":"10.32074\/1591-951X-N979_ref15","doi-asserted-by":"crossref","unstructured":"Ryuta Watanabe R, Masashi Maekawa M, Miki Hieda M et al. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex. Mol Biol Cell. 2020;31:478-490. https:\/\/doi.org\/10.1091\/mbc.","DOI":"10.1091\/mbc.E19-08-0456"},{"key":"10.32074\/1591-951X-N979_ref16","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Llodr\u00e0 S, Segal\u00e9s L, Juanpere N, et al. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. Prostate. 2021;81:1267-1277. https:\/\/doi.org\/10.1002\/pros.24218.","DOI":"10.1002\/pros.24218"},{"key":"10.32074\/1591-951X-N979_ref17","unstructured":"Clark A, Burleson M. SPOP and cancer: a systematic review. Am J Cancer Res. 2020;10:704-726."},{"key":"10.32074\/1591-951X-N979_ref18","doi-asserted-by":"crossref","unstructured":"Zakari S, Ekenwaneze CC, Amadi EC, et al. Unveiling the latest insights into Androgen Receptors in Prostate Cancer. Int J Med Biochem, 2024;7:101-113. https:\/\/doi.org\/10.14744\/ijmb.2024.93585.","DOI":"10.14744\/ijmb.2024.93585"},{"key":"10.32074\/1591-951X-N979_ref19","doi-asserted-by":"crossref","unstructured":"Cavalcante L, Deshmukh SK, Ribeiro JR ate al. Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers. JCO Precis Oncol. 2023;7:e2300088. https:\/\/doi.org\/10.1200\/PO.23.00088.","DOI":"10.1200\/PO.23.00088"},{"key":"10.32074\/1591-951X-N979_ref20","doi-asserted-by":"crossref","unstructured":"Kciuk M, Ko\u0142at D, Ka\u0142uzi\u0144ska-Ko\u0142at Z, et al. PD-1\/PD-L1 and DNA Damage Response in Cancer. Cells. 2023;12:530. https:\/\/doi.org\/10.3390\/cells12040530.","DOI":"10.3390\/cells12040530"},{"key":"10.32074\/1591-951X-N979_ref21","doi-asserted-by":"crossref","unstructured":"Chen M, Linstra R and Vugt M. Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2022;1877:188661. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188661.","DOI":"10.1016\/j.bbcan.2021.188661"},{"key":"10.32074\/1591-951X-N979_ref22","doi-asserted-by":"crossref","unstructured":"Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2017;66:794-801. https:\/\/doi.org\/10.1136\/gutjnl-2015-310839.","DOI":"10.1136\/gutjnl-2015-310839"},{"key":"10.32074\/1591-951X-N979_ref23","doi-asserted-by":"crossref","unstructured":"Liu D, Takhar M, Alshalalfa M, et al. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol 2018:2018:PO.18.00036. https:\/\/doi.org\/10.1200\/PO.18.00036.","DOI":"10.1200\/PO.18.00036"},{"key":"10.32074\/1591-951X-N979_ref24","doi-asserted-by":"crossref","unstructured":"Nakazawa M, Fang M, Marshall CH, et al. Clinical and genomic features of SPOP-mutant prostate cancer. Prostate. 2022;82:260-268. https:\/\/doi.org\/10.1002\/pros.24269.","DOI":"10.1002\/pros.24269"},{"key":"10.32074\/1591-951X-N979_ref25","doi-asserted-by":"crossref","unstructured":"Sedhom R, Antonarakis ES. Clinical implications of mismatch repair deficiency in prostate cancer. Future Oncol. 2019;15:2395-2411. https:\/\/doi.org\/10.2217\/fon-2019-0068.","DOI":"10.2217\/fon-2019-0068"},{"key":"10.32074\/1591-951X-N979_ref26","doi-asserted-by":"crossref","unstructured":"Rebuzzi SE, Rescigno P, Catalano F, et al. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers. 2022;14:1245. https:\/\/doi.org\/10.3390\/cancers14051245.","DOI":"10.3390\/cancers14051245"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:06:47Z","timestamp":1763392007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-n979","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"4"}}